Grants and Contributions:
Title:
In vivo validation of ProteinQure’s SORT1 delivery platform for triple negative breast cancer in patient relevant Trodelvy resistant animal models
Agreement Number:
1010963
Agreement Value:
$206,800.00
Agreement Date:
Aug 16, 2023 - Apr 30, 2024
Description:
ProteinQure is going to show the potential of its SORT1 delivery platform by demonstrating the ability to cure Trodelvy/Enhertu resistant Triple Negative Breast Cancer (the most deadly form of breast cancer with no treatments). This IRAP project will involve the design and creation of animal models based on patient samples (PDX) which recapitulate acquired resistance to Trodelvy/Enhertu. While simpler PDX models would be sufficient for regulatory purposes, more advanced models increase the commercial potential and likelihood of success for the SORT1 platform in TNBC.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5V 2L1
Reference Number:
172-2023-2024-Q3-1010963
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
788609683
Recipient Type:
For-profit organization
Recipient's Legal Name:
ProteinQure Inc.
Federal Riding Name:
Spadina--Fort York
Federal Riding Number:
35101
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410